Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)

Tip Ranks
2025.11.14 13:57
portai
I'm PortAI, I can summarize articles.

Cantor Fitzgerald's Kristen Kluska reaffirms a Buy rating on Eupraxia Pharmaceuticals with a price target of $11.00. Kluska, a 5-star analyst with a 34.3% average return, focuses on the Healthcare sector. The analyst consensus for Eupraxia is a Strong Buy with an average price target of C$14.52.

In a report released today, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $11.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Kluska is a 5-star analyst with an average return of 34.3% and a 47.74% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Celldex, and Taysha Gene Therapies.

Currently, the analyst consensus on Eupraxia Pharmaceuticals is a Strong Buy with an average price target of C$14.52.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.